

Gegliedertes Schriftenverzeichnis Prof. Dr. med. Utz Krug

Nr.	Originalarbeiten in Zeitschriften *: geteilte Erst / Letztautorenschaften	Impact Factor
1	Schulten T, Meyer A, Krug U , Lehmann HC. Differential diagnosis of Guillain-Barré syndrome: steroid-responsive radiculopathy in Evans syndrome. Neurol Res Pract. 2024 Sep 20;6(1):45.	
2	Rausch C, Arnreich C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Bücklein V, Subklewe M, Sauerland C, Görlich D, Krug U , Berdel WE, Wörmann BJ, Hiddemann W, Braess J, von Bergwelt-Baildon M, Spiekermann K, Metzeler KH, Herold T. Friday Leukemia-a Structural Phenomenon. Dtsch Arztebl Int. 2024 Feb 9;121(3):94-95.	8,251
3	Georgi JA, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, Valk P, Linch D, Herold T, Duployez N, Taube F, Middeke JM, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Haferlach C, Koch S, Berdel WE, Woermann BJ, Krug U , Braess J, Hiddemann W, Spiekermann K, Boertjes EL, Hills RK, Burnett A, Ehninger G, Metzeler K, Rothenberg-Thurley M, Dufour A, Dombret H, Pautas C, Preudhomme C, Fenwarth L, Bornhäuser M, Gale R, Thiede C. Prognostic impact of CEBPA mutational subgroups in adult AML. Leukemia. 2024 Feb;38(2):281-290.	12,883
4	Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U , Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 Jan;38(1):45-57.	12,883
5	Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U , Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia. 2023 Nov;37(11):2282-2285.	12,883
6	Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Röllig C, Middeke JM, Oelschlägel U, Krug U , Sauer T, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Kroschinsky F, Thiede C; Study Alliance Leukemia (SAL). UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023 May 26;13(1):88.	12,8
7	Eckardt JN, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi JA, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, Krug U , Braess J, Görlich D, Sauerland C, Woermann B, Herold T, Hiddemann W, Müller-Tidow C, Serve H, Baldus CD, Schäfer-Eckart K, Kaufmann M, Krause SW, Hänel M, Berdel WE, Schliemann C, Mayer J, Hanoun M, Schetelig J, Wendt K, Bornhäuser M, Thiede C, Middeke JM. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond).	unter JCR review

	2023 May 17;3(1):68.	
8	Brulke F, Para S, Alt-Epping B, Tewes M, Bäumer M, Haberland B, Mayer-Steinacker R, Hopprich A, de Wit M, Grabe M, Bender-Säbelkamp S, Weßling C, Aulmann C, Gerlach C, Regincos P, Fischer F, Haarmann S, Huys T, Drygas S, Rambau A, Kiani A, Schnabel A, Buhl C, Seipke S, Hiemer S, Polata S, Meßmann M, Hansmeier A, Anastasiadou L, Letsch A, Wecht D, Hellberg-Naegele M, Krug U , Wedding U, van Oorschot B. Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project. J Cancer Res Clin Oncol. 2023 Sep;149(11):8829-8842	3,6
9	Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, Görlich D, Krug U , Berdel WE, Woermann BJ, Hiddemann W, Braess J, von Bergwelt-Baildon M, Spiekermann K, Herold T, Metzeler KH. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023 Jun;37(6):1234-1244.	12,883
10	Niederwieser D, Lang T, Kahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U* , Hoffmann VS*. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023 Mar;102(3):547-561.	4,03
11	Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U* , Schliemann C*. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy. Ann Hematol. 2023 Jan;102(1):63-72.	4,03
12	Batcha AMN, Buckup N, Bamopoulos SA, Jurinovic V, Rothenberg-Thurley M, Gittinger H, Ksienzyk B, Dufour A, Schneider S, Kontro M, Saad J, Heckmann CA, Sauerland C, Görlich D, Berdel WE, Wörmann BJ, Krug U , Braess J, Mansmann U, Hiddemann W, Spiekermann K, Metzeler KH, Herold T. Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML. Blood Adv. 2023 Mar 28;7(6):1040-1044.	7,6
13	Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U , Braess J, Krämer A, Hochhaus A, Scholl S, Hilgendorf I, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022 Sep 5;15(1):126.	28,5

14	Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, Spiekermann K, Krug U , Braess J, Görlich D, Sauerland CM, Woermann B, Herold T, Berdel WE, Hiddemann W, Kroschinsky F, Schetelig J, Platzbecker U, Müller-Tidow C, Sauer T, Serve H, Baldus C, Schäfer-Eckart K, Kaufmann M, Krause S, Hänel M, Schliemann C, Hanoun M, Thiede C, Bornhäuser M, Wendt K, Middeke JM. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. <i>Haematologica</i> . 2023 Mar 1;108(3):690-704.	11,047
15	Middeke JM, Metzeler KH, Röllig C, Krämer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U , Braess J, Krämer A, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Görlich D, Sauerland C, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Wörmann B, Sockel K, von Bonin M, Herold T, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhäuser M, Stölzel F, Thiede C. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Adv</i> . 2022 Mar 8;6(5):1394-1405.	7,6
16	Moser C, Jurinovic V, Sagebiel-Kohler S, Ksienzyk B, Batcha AMN, Dufour A, Schneider S, Rothenberg-Thurley M, Sauerland CM, Görlich D, Berdel WE, Krug U , Mansmann U, Hiddemann W, Braess J, Spiekermann K, Greif PA, Vosberg S, Metzeler KH, Kumbink J, Herold T. A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia. <i>Blood Adv</i> . 2021 Nov 23;5(22):4752-4761.	7,6
17	Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U , Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> . 2022 Jan 6;139(1):87-103.	22,113
18	Röllig C, Serve H, Noppeney R, Hanoun M, Krug U , Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia (SAL). Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> . 2021 Sep;35(9):2517-2525.	12,883
19	Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U , Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. <i>Leukemia</i> . 2020 Dec;34(12):3161-3172.	12,883

20	Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U* , Schliemann C*. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 Oct 10;37(29):2632-2642.	50,717
21	Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U , Metzeler KH, Mikesch JH, Herold T, Schliemann C. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia. 2019 Dec;33(12):2830-2841.	12,883
22	Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk RF, Krug U , Goeldner RG, Hilbert J, Taube T, Ottmann OG. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. Br J Haematol. 2019 May;185(3):583-587.	8,615
23	Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U , Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018 Nov;103(11):1853-1861.	11,047
24	Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U , Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. Br J Haematol. 2019 Mar;184(6):1018-1021.	8,615
25	Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U , Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 Nov;103(11):e514-e518.	11,047
26	Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U , Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. Eur J Haematol. 2018 Feb;100(2):154-162.	3,674

27	Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U , Kropff MH, Thoennissen NH, Berdel WE. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. <i>Acta Haematol.</i> 2017;137(3):163-172.	3,068
28	Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U . A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. <i>PLoS One.</i> 2016 Oct 7;11(10):e0164499.	3,752
29	Varghese J, Holz C, Neuhaus P, Bernardi M, Boehm A, Ganzer A, Gore S, Heaney M, Hochhaus A, Hofmann WK, Krug U , Müller-Tidow C, Smith A, Weltermann A, de Witte T, Hehlmann R, Dugas M. Key Data Elements in Myeloid Leukemia. <i>Stud Health Technol Inform.</i> 2016;228:282-6.	0,73
30	Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiez P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullermann C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U . Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. <i>PLoS One.</i> 2016 Aug 30;11(8):e0160871.	3,752
31	Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U , Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. <i>Haematologica.</i> 2016 Oct;101(10):1208-1215.	11,047
32	Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstantin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U , Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <i>Blood.</i> 2016 Aug 4;128(5):686-98.	22,113
33	Büchner T, Krug UO , Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. <i>Leukemia.</i> 2016 Aug;30(8):1781-4.	12,883
34	Krug U , Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. <i>Leukemia.</i> 2016 Jun;30(6):1230-6.	12,883

35	Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U , Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncol</i> . 2015 Dec;16(16):1691-9.	54,443
36	Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage R, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U . Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. <i>Leukemia</i> . 2016 Mar;30(3):555-61.	12,883
37	Sauer T, Arteaga MF, Isken F, Rohde C, Hebestreit K, Mikesch JH, Stelljes M, Cui C, Zhou F, Göllner S, Bäumer N, Köhler G, Krug U , Thiede C, Ehninger G, Edemir B, Schlenke P, Berdel WE, Dugas M, Müller-Tidow C. MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. <i>Exp Hematol</i> . 2015 Sep;43(9):794-802	3,249
38	Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U , Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S. Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia. <i>PLoS One</i> . 2015 May 21;10(5):e0125783.	3,752
39	Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Sauntharajah Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, Pollyea DA, Krug U , Berdel WE, Klein HU, Dugas M, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S, Müller-Tidow C, Maciejewski JP. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. <i>Cancer Cell</i> . 2015 May 11;27(5):658-70.	38,585
40	Sauer T, Silling G, Groth C, Rosenow F, Krug U , Görlich D, Evers G, Albring J, Besoke R, Mesters RM, Müller-Tidow C, Kessler T, Büchner T, Berdel WE, Stelljes M. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. <i>Bone Marrow Transplant</i> . 2015 Apr;50(4):485-92.	5,609
41	Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U , Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. <i>J Clin Oncol</i> . 2015 Feb 10;33(5):403-10.	50,717

42	Pastore F, Greif PA, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Braess J, Sauerland CM, Heinecke A, Krug U , Berdel WE, Buechner T, Woermann B, Hiddemann W, Spiekermann K. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS One. 2014 Oct 9;9(10):e109759.	3,752
43	Pastore F, Dufour A, Benthaut T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U , Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014 May 20;32(15):1586-94.	50,717
44	Stelljes M*, Krug U* , Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Büchner T. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014 Feb 1;32(4):288-96.	50,717
45	Rizzieri D, Vey N, Thomas X, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U . A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leuk Lymphoma. 2014 Sep;55(9):2114-9.	2,996
46	Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U , Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield CD. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014 Feb;99(2):308-13.	11,047
47	Serve H*, Krug U* , Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013 Sep 1;31(25):3110-3118.	50,717
48	Mikesch JH, Kuhlmann M, Demant A, Krug U , Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013 Aug;92(8):1041-8.	4,03
49	Rosenow F, Berkemeier A, Krug U , Müller-Tidow C, Gerss J, Silling G, Groth C, Wieacker P, Bogdanova N, Mesters R, Büchner T, Kienast J, Berdel WE, Stelljes M. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013 Aug;48(8):1070-6.	5,609

50	Krug U , Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Röllig C, Thiede C, Noppeney R, Stelljes M, Büchner T, Koschmieder S, Dührsen U, Serve H, Ehninger G, Berdel WE, Müller-Tidow C. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. PLoS One. 2012;7(12):e52695.	3,752
51	Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, Krug U , Timmermann B, Marra A, Hillejan L, Wiebe K, Berdel WE, Schwab A, Müller-Tidow C. Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One. 2012;7(12):e44591.	3,752
52	Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U , Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. 2013 Jan;92(1):41-52.	4,03
53	Büchner T, Schlenk RF, Schaich M, Döhner K, Kral R, Krauter J, Heil G, Krug U , Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012 Oct 10;30(29):3604-10.	50,717
54	Kyme P, Thoennissen NH, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO , Lee K, Müller-Tidow C, Berdel WE, Hardy WD, Gombart AF, Koeffler HP, Liu GY. C/EBP ϵ mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest. 2012 Sep 4;122(9):3316-29.	19,456
55	O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO , Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep;158(5):581-8.	8,615
56	Thoennissen GB, Thoennissen NH, Fritz F, Hilbig A, Kerkhoff A, Liersch R, Krug U , Koschmieder S, Müller-Tidow C, Mesters R, Kropff M, Berdel WE. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. Ann Hematol. 2012 Sep;91(9):1419-25.	4,03
57	Mohr M, Hartig I, Kessler T, Hamisch C, Kliesch S, Krug U , Spieker T, Semik M, Wiebe K, Pühse G, Hertle L, Liersch R, Müller-Tidow C, Mesters RM, Berdel WE. High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases. Bone Marrow Transplant. 2012 Oct;47(10):1321-5.	5,609
58	Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Bäumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U , Koschmieder S, Büchner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Müller-Tidow C. Genome wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012 Mar 8;119(10):2346-57.	22,113

59	Melzer N, Barth PJ, Müller KM, Foss HD, Krug U , Schilling M, Marziniak M, Grauer OM, Wiendl H. Rapidly progressive B-cell dominated inflammatory neuropathy and littoral cell angioma of the spleen associated with plasmablastic B-cell lymphoma. Leuk Lymphoma. 2012 Jun;53(6):1242-4.	2,996
60	Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U , Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol. 2012 Apr;23(4):990-6.	51,769
61	Krug U , Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; for the German Acute Myeloid Leukaemia Cooperative Group and the Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010 Dec 11;376(9757):2000-8.	202,731
62	Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U , Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2010 Oct 1;28(28):4333-8.	45,3
63	Hömme C*, Krug U* , Tidow N, Schulte B, Köhler G, Serve H, Bürger H, Berdel WE, Dugas M, Heinecke A, Büchner T, Koschmieder S, Müller-Tidow C. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. Oncol Rep. 2010 Jul;24(1):47-56.	5,945
64	Thoennissen NH*, Krug UO* , Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koefler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010 Apr 8;115(14):2882-90.	22,113
65	Krug U , Buchner T, Fassbinder T, Gaubitz M, Berdel WE. Clinical image: Lupus erythematosus cells in ascites fluid. Arthritis Rheum. 2009 Mar;60(3):859.	7,046
66	Bulk E, Sargin B, Krug U , Hascher A, Jun Y, Knop M, Kerkhoff C, Gerke V, Liersch R, Mesters RM, Hotfilder M, Marra A, Koschmieder S, Dugas M, Berdel WE, Serve H, Müller-Tidow C. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009 Jan 1;15(1):22-9.	13,801
67	Krug U , Yasmeeen A, Beger C, Bäumer N, Dugas M, Berdel WE, Müller-Tidow C. Cyclin A1 regulates WT1 expression in acute myeloid leukemia cells. Int J Oncol. 2009 Jan;34(1):129-36.	5,884
68	Thoennissen NH, Keyvani K, Voelker HU, Bremer J, Krug U , Müller-Tidow C, Koch P, Müller-Hermelink HK, Berdel WE. Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation. J Clin Oncol. 2008 Sep 20;26(27):4509-11.	45,3

69	Kessler T, Mohr M, Müller-Tidow C, Krug U , Brunnberg U, Mohr B, Schliemann C, Sauerland C, Serve H, Büchner T, Berdel WE, Mesters RM. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. <i>Leuk Res.</i> 2008 Mar;32(3):491-4.	3,715
70	Koenecke C, Kleine M, Schrem H, Krug U , Nashan B, Neipp M, Ganser A, Hertenstein B, Klempnauer J. Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation. <i>Int J Hematol.</i> 2006 Apr;83(3):271-4.	2,319
71	Gombart AF*, Krug U* , O'Kelly J, An E, Vegesna V, Koeffler HP. Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency. <i>J Leukoc Biol.</i> 2005 Nov;78(5):1153-65.	6,011
72	Ikezoe T, Tanosaki S, Krug U , Liu B, Cohen P, Taguchi H, Koeffler HP. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. <i>Blood.</i> 2004 Jul 1;104(1):237-42.	22,113
73	Chien W, Tidow N, Williamson EA, Shih LY, Krug U , Kettenbach A, Fermin AC, Roifman CM, Koeffler HP. Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway. <i>J Biol Chem.</i> 2003 Jul 25;278(30):27413-20.	5,486
74	de Vos S*, Krug U* , Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W, Grogan TM, Said JW, Koeffler HP. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. <i>Diagn Mol Pathol.</i> 2003 Mar;12(1):35-43.	1,474
75	de Vos S, Hofmann WK, Grogan TM, Krug U , Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP, Said JW. Gene expression profile of serial samples of transformed B-cell lymphomas. <i>Lab Invest.</i> 2003 Feb;83(2):271-85.	5,502
76	Kaferstein A, Krug U , Tiesmeier J, Aivado M, Faulhaber M, Stadler M, Krauter J, Germing U, Hofmann WK, Koeffler HP, Ganser A, Verbeek W. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. <i>Leukemia.</i> 2003 Feb;17(2):343-9.	12,883
77	Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U , Fermin AC, Heaney A, Miller CW, Koeffler HP. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. <i>Leuk Res.</i> 2002 May;26(5):451-7.	3,715
78	Jones LC, Lin ML, Chen SS, Krug U , Hofmann WK, Lee S, Lee YH, Koeffler HP. Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. <i>Blood.</i> 2002 Mar 15;99(6):2032-6.	22,113
79	Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U , Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. <i>Blood.</i> 2002 Feb 15;99(4):1332-40.	22,113
80	Miller CW, Ikezoe T, Krug U , Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. <i>Genes Chromosomes Cancer.</i> 2002 Jan;33(1):17-21.	4,263

81	Krauter J, Wattjes MP, Nagel S, Heidenreich O, Krug U , Kafert S, Bunjes D, Bergmann L, Ganser A, Heil G. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol. 1999 Oct;107(1):80-5.	8,615
82	Tiedge M, Krug U , Lenzen S. Modulation of human glucokinase intrinsic activity by SH reagents mirrors post-translational regulation of enzyme activity. Biochim Biophys Acta. 1997 Feb 8;1337(2):175-90.	4,117

Nr.	Übersichtsarbeiten *: geteilte Erst / Letztautorenschaften	Impact Factor
1	Extermann M, Artz A, Rebollo MA, Klepin HD, Krug U , Loh KP, Mims AS, Neuendorff N, Santini V, Stauder R, Vey N; SIOG. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol. 2024 Mar;15(2):101626.	3,929
2	Krug U , Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddemann W, Büchner T. Therapy of older persons with acute myeloid leukaemia. Leuk Res. 2017 Sep;60:1-10.	3,715
3	Liersch R, Müller-Tidow C, Berdel WE, Krug U . Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. Br J Haematol. 2014 Apr;165(1):17-38.	8,615
4	Krug U , Büchner T, Berdel WE, Müller-Tidow C. The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int. 2011 Dec;108(51-52):863-70.	8,251
5	Mohr M, Kessler, T, Krug U , Hoffknecht P, Schmidt LH, Wiebe K, Berdel WE, Wiewrodt R. Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie 2010 Apr;24(2):97.	0,1
6	Krug U , Lübbert M, Büchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol. 2010 Mar;17(2):85-90.	3,218
7	Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U , Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009 Feb;88(2):97-110.	4,03
8	Büchner T*, Krug U* , Berdel WE, Heinecke A, Sauerland MC, Wörmann B, Hiddemann W. Maintenance for acute myeloid leukemia revisited. Curr Treat Options Oncol. 2007 Aug;8(4):296-304.	5,08
9	Müller-Tidow C, Krug U , Brunnberg U, Berdel WE, Serve H. Tyrosinkinase als Ziele neuer onkologischer Therapien: Aussichten und Probleme. Dtsch Arztebl 2007;104(19):A-1312-9.	8,251
10	Krug U , Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002 May 13;21(21):3475-95.	8,756

Nr.	Editorials	Impact Factor
1	Krug U , Berdel WE. Smoking and AML - another piece in the puzzle. Br J Haematol. 2020 Jul;190(2):143.	8,615

Nr.	Bücher - Herausgeber
1	Steffen Koschmieder & Utz Krug (Ed.). Myeloid Leukemia - Basic Mechanisms of Leukemogenesis. Intech 2011, 496 pages, ISBN 978-953-307-789-5.
2	Steffen Koschmieder & Utz Krug (Ed.). Myeloid Leukemia - Clinical Diagnosis and Treatment. Intech 2012, 308 pages, ISBN 978-953-307-886-1.
Nr.	Buchbeiträge
1	Krug U . Akute myeloische Leukämie und verwandte hämatopoetische Neoplasien. In: Karl-Anton Kreuzer, Jörg Beyer (Hrsg.). Hämatologie und Onkologie. Fallorientierte Darstellung – rationale Diagnostik und Therapie. Thieme Verlag 2016; 264-274.
2	Krug U . Leukämien unklarer Linienzugehörigkeit. In: Karl-Anton Kreuzer, Jörg Beyer (Hrsg.). Hämatologie und Onkologie. Fallorientierte Darstellung – rationale Diagnostik und Therapie. Thieme Verlag 2016; 274-277.
3	Krug U . AML Scoringsysteme – Ist meins besser als deins? In: Gerhard Ehninger, Friedrich Overkamp (Hrsg.). Colloquium Onkologie 15. LUKON Verlagsgesellschaft mbH 2013; 127-149.
4	Müller-Tidow C., Krug U . Molekulargenetische Veränderungen und Prognosefaktoren bei der AML. In: Wolf-Karsten Hofmann / Hubert Serve (Hrsg.). Aktuelle Therapiekonzepte bei akuter myeloischer Leukämie (AML). UNI-MED 2012; 50-56.
5	Krug U , Sauer T, Müller-Tidow C. Therapieentscheidungen bei älteren Patienten mit AML. In: Wolf-Karsten Hofmann / Hubert Serve (Hrsg.). Aktuelle Therapiekonzepte bei akuter myeloischer Leukämie (AML). UNI-MED 2012; 50-56.
6	Krug U , Serve H, Müller-Tidow C, Berdel WE. Therapie mit neuen Substanzen. In: Gerhard Ehninger / Hartmut Link / Wolfgang E. Berdel (Hrsg.). Akute myeloische Leukämie. Deutscher Ärzteverlag 2008;104-20.
7	Schaich M, Ehninger G, Link H, Krug U , Serve H, Berdel WE, Hänel M, Schuler U, Reichle A. Therapiestudien. In: Gerhard Ehninger / Hartmut Link / Wolfgang E. Berdel (Hrsg.). Akute myeloische Leukämie. Deutscher Ärzteverlag 2008; 241-55.
8	Krug U , Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, Berdel WE. New molecular therapy targets in acute myeloid leukemia. In: Manfred Dietel (Ed). Recent Results in Cancer Research. Edition 176: Targeted Therapies in Cancer. Springer Verlag 2007;243-62.